Loading...

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors

In Chronic Myeloid Leukemia (CML), successful treatment requires accurate molecular monitoring to evaluate disease response and provide timely interventions for patients failing to achieve the desired outcomes. We wanted to determine whether measuring BCR-ABL1 mRNA doubling-times (DTs) could disting...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Front Oncol
Main Authors: Pennisi, Maria Stella, Stella, Stefania, Vitale, Silvia Rita, Puma, Adriana, Di Gregorio, Sandra, Romano, Chiara, Tirrò, Elena, Massimino, Michele, Antolino, Agostino, Siragusa, Sergio, Mannina, Donato, Impera, Stefana, Musolino, Caterina, Mineo, Giuseppe, Martino, Bruno, Zammit, Valentina, Di Raimondo, Francesco, Manzella, Livia, Stagno, Fabio, Vigneri, Paolo
Format: Artigo
Sprog:Inglês
Udgivet: Frontiers Media S.A. 2019
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6700306/
https://ncbi.nlm.nih.gov/pubmed/31456947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00764
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!